The journal Urologia Internationalis publishes a pharmacoeconomics analysis of MV140 (UROMUNE) in women suffering from recurrent urinary tract infections conducted at the Urology Department of the Complejo Hospitalario Universitario de Albacete (Spain).

The study, conducted prospectively under real-world conditions, concludes that MV140 results in very significant annual savings in the healthcare costs associated with these infections. The savings were calculated per patient/year taking into account only direct healthcare costs and drug consumption before and after MV140 treatment.

MV140 is a sublingual mucosal bacterial vaccine developed by INMUNOTEK that significantly reduces the number of infectious episodes and the consumption of antibiotics.

+info